Enzyme induction and beta-adrenergic receptor blocking drugs

Area of Science:

• Pharmacology
• Drug Metabolism
• Cardiovascular Therapeutics

Background:

• Beta-adrenergic receptor blockers requiring metabolism are susceptible to drug interactions via enzyme induction.
• Limited human data exists for interactions involving propranolol, metoprolol, and alprenolol.
• Environmental factors like smoking influence propranolol's oral clearance in younger populations.

Purpose of the Study:

• To investigate the impact of enzyme induction on the pharmacokinetic disposition of beta-adrenergic receptor blockers.
• To quantify the effect of inducing agents (rifampicin, pentobarbitone) on drug clearance.
• To assess the implications for therapeutic efficacy and the need for dosage modifications.

Main Methods:

• Long-term, within-subject studies comparing drug clearances before and after administration of enzyme inducers.
• Analysis of pharmacokinetic parameters including intrinsic clearance, liver blood flow, and protein binding.
• Evaluation of dose and time dependency of enzyme induction effects.

Main Results:

• Oral clearance of metoprolol, alprenolol, and propranolol increased by 50%-500% following enzyme induction.
• Enzyme induction affects multiple pharmacokinetic factors, leading to complex disposition changes.
• Inter-individual variation in drug metabolism remains consistent before and after induction.

Conclusions:

• Enzyme induction significantly alters the pharmacokinetics of beta-adrenergic receptor blockers.
• The substantial reduction in steady-state drug concentrations can lead to diminished pharmacodynamic responses.
• Dosage modification is crucial to maintain therapeutic effectiveness in patients undergoing enzyme induction.